{'fraction_non_alphanumeric': 0.023863636363636365, 'fraction_numerical': 0.013636363636363636, 'mean_word_length': 5.574626865671642, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Vecuronium for muscle relaxation in patients with dystrophia myotonica.

ystrophia myotonica is an inherited tonic muscle disease with a progressive atrophic D component. Its prevalence is 3-5/100,000 of the population (1). The clinical features of the disease and its anesthesiologic implications were reviewed thoroughly by Aldridge (2); however, Aldridge did not have quantitative data on the effect of muscle relaxants in such patients. Since then, only a few anecdotal reports on dystrophia myotonica have appeared in which neuromuscular transmission had been recorded (3-7). All of these papers were single case reports relying on different techniques of anesthesia and neuromuscular monitoring. We present data on neuromuscular block following titrated doses of vecuronium administered to three patients with dystrophia myotonica during nitrous oxide-isoflurane anesthesia.